Increasing protection after tamoxifen: Insights from the extended adjuvant aromatase inhibitor trials

Journal of Cancer Research and Clinical Oncology

Volumn 134, Issue 1, 2008, Pages 7-17

  Rose, Carsten ^a  

^a LUND UNIVERSITY HOSPITAL   (Sweden)

Author keywords

Anastrozole; Breast cancer recurrence; Extended adjuvant therapy; Letrozole; Tamoxifen

Indexed keywords

AMINOGLUTETHIMIDE; ANASTROZOLE; AROMATASE INHIBITOR; EXEMESTANE; LETROZOLE; PLACEBO; TAMOXIFEN;

ADJUVANT THERAPY; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ARTHRITIS; BONE PAIN; BREAST CANCER; CANCER; CANCER RELAPSE; CANCER RESEARCH; CLINICAL TRIAL; COLORECTAL CANCER; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; COST EFFECTIVENESS ANALYSIS; DRUG COST; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG SUBSTITUTION; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOMETRIUM CANCER; FATIGUE; HORMONAL THERAPY; HOT FLUSH; HUMAN; HYPERCHOLESTEROLEMIA; MONOTHERAPY; MORBIDITY; MORTALITY; MYALGIA; OSTEOPOROSIS; POSTMENOPAUSE; PRIORITY JOURNAL; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; REVIEW; THROMBOEMBOLISM; TREATMENT DURATION; TREATMENT OUTCOME; VAGINA BLEEDING;

ANTINEOPLASTIC AGENTS, HORMONAL; AROMATASE INHIBITORS; BREAST NEOPLASMS; CHEMOTHERAPY, ADJUVANT; CLINICAL TRIALS AS TOPIC; FEMALE; HUMANS; PRACTICE GUIDELINES AS TOPIC; TAMOXIFEN;

EID: 35848960553     PISSN: 01715216     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00432-007-0324-8     Document Type: Review

References (45)

1. Abetz L, Barghout V, de la Loge C, Arbuckle A (2005) No differences in quality of life for letrozole relative to placebo in post-menopausal women with early breast cancer regardless of age: results from the MA-17 study. Eur J Cancer Suppl 3:96 (#342, abstract)
2. Baum M (2004) Current status of aromatase inhibitors in the management of breast cancer and critique of the NCIC MA-17 trial. Cancer Control 11:217-221
3. Bhatnagar AS, Batzl C, Hausler A, Schieweck K, Lang M, Trunet PF (1996) Pharmacology of non-steroidal aromatase inhibitors. In: Pasqualini JR, Katzenellenbogen BS (eds) Hormone-dependent cancer. Marcel Dekker, New York, pp 155-168
4. Brufsky A, Harker WG, Beck JT, Carroll R, Tan-Chiu E, Seidler C, Hohneker J, Lacerna L, Petrone S, Perez EA (2007) Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer. J Clin Oncol 25:829-836
5. Bundred N, Campbell I, Coleman R, DeBoer R, Eidtmann H, Frassolati A, Llombart A, Monnier A, Neven P, Dias R (2006) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer (ZO-FAST study). Eur J Cancer Suppl 4:48 (#12, abstract)
6. Davidson N, Neven P, Llombart A, Bundred N, Monnier A, DeBoer R, Giardina G, Editmann H, Schenk N, Dodion P (2005) Zoledronic acid in the prevention of cancer treatment-induced bone loss in postmenopausal women receiving letrozole as adjuvant therapy for early breast cancer. Breast 14(Suppl 1):S44 (#P105, abstract)
7. Delea TE, Karnon J, Smith RE, Johnston SR, Brandman J, Sung JC, Gross PE (2006) Cost-effectiveness of extended adjuvant letrozole therapy after 5 years of adjuvant tamoxifen therapy in postmenopausal women with early-stage breast cancer. Am J Manag Care 12:374-386
8. Earle CC, Chapman RH, Baker CS, Bell CM, Stone PW, Sandberg EA, Neumann PJ (2000) Systematic overview of cost-utility assessments in oncology. J Clin Oncol 18:3302-3317
9. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (1998) Tamoxifen for early breast cancer: an overview of the randomized trials. Lancet 351:1451-1467
10. Early Breast Cancer Trialists' Collaborative Group (EBCTCG) (2005) Effects of chemotherapy and hormonal therapy for early breast cancer on recurrence and 15-year survival: an overview of the randomised trials. Lancet 365:1687-1717
11. Fisher B, Costantino J, Redmond C, Poisson R, Bowman D, Couture J, Dimitrov NV, Wolmark N, Wickerham DL, Fisher ER (1989) A randomized clinical trial evaluating tamoxifen in the treatment of patients with node-negative breast cancer who have estrogen-receptor-positive tumors. N Engl J Med 320:479-484
12. Fisher B, Dignam J, Bryant J, DeCillis A, Wickerham DL, Wolmark N, Costantino J, Redmond C, Fisher ER, Bowman DM, Deschenes L, Dimitrov NV, Margolese RG, Robidoux A, Shibata H, Terz J, Paterson AH, Feldman MI, Farrar W, Evans J, Lickley HL (1996) Five versus more than five years of tamoxifen therapy for breast cancer patients with negative lymph nodes and estrogen receptor-positive tumors. J Natl Cancer Inst 88:1529-1542
13. Fisher B, Costantino JP, Wickerham DL, Redmond CK, Kavanah M, Cronin WM, Vogel V, Robidoux A, Dimitrov N, Atkins J, Daly M, Wieand S, Tan-Chiu E, Ford L, Wolmark N (1998) Tamoxifen for prevention of breast cancer: report of the National Surgical Adjuvant Breast and Bowel Project P-1 study. J Natl Cancer Inst 90:1371-1388
14. Fisher B, Dignam J, Bryant J, Wolmark N (2001) Five versus more than five years of tamoxifen for lymph node-negative breast cancer: updated findings from the National Surgical Adjuvant Breast and Bowel Project B-14 randomized trial. J Natl Cancer Inst 93:684-690
15. Furr BJ, Jordan VC (1984) The pharmacology and clinical uses of tamoxifen. Pharmacol Ther 25:127-167
16. Goss PE (2003) Breast cancer prevention-clinical trials strategies involving aromatase inhibitors. J Steroid Biochem Mol Biol 86:487-493
17. Goss PE (2004) Changing clinical practice: extending the benefits of adjuvant endocrine therapy in breast cancer. Semin Oncol 31(Suppl 12):15-22
18. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Therasse P, Palmer MJ, Pater JL (2003) A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349:1793-1802
19. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione MM, Tu D, Shepherd LE, Pater JL (2004) Updated analysis of the NCIC CTG MA.17 randomized placebo (P) controlled trial of letrozole (L) after five years of tamoxifen in postmenopausal women with early stage breast cancer. J Clin Oncol 22(14S) (#847, abstract)
20. Goss PE, Ingle JN, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Tu D, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Pater JL (2005a) Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17. J Natl Cancer Inst 97:1262-1271
21. Goss PE, Ingle JN, Tu D (2005b) NCIC CTG MA17: disease free survival according to estrogen receptor and progesterone receptor status of the primary tumor. Breast Cancer Res Treat 94(Suppl 1):S98 (#2042, abstract)
22. Goss PE, Ingle JN, Palmer MJ, Shepherd LE, Tu D (2005c) Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. Breast Cancer Res Treat 94(Suppl 1):S13 (#16, abstract)
23. Ingle J, Tu D, Shepherd L, Palmer M, Pater J, Goss P (2006a) NCIC CTG MA.17: intent to treat analysis (ITT) of randomized patients after a median follow-up of 54 months. J Clin Oncol 24(18S):15s (#549, abstract)
24. Ingle JN, Tu D, Pater JL, Martino S, Robert NJ, Muss HB, Piccart MJ, Castiglione M, Shepherd LE, Pritchard KI, Livingston RB, Davidson NE, Norton L, Perez EA, Abrams JS, Cameron DA, Palmer MJ, Goss PE (2006b) Duration of letrozole treatment and outcomes in the placebo-controlled NCIC CTG MA.17 extended adjuvant therapy trial. Breast Cancer Res Treat 99:295-300
25. Jakesz R, Samonigg H, Greil R, Gnant M, Schmid M, Kwasny W, Kubista E, Mlineritsch B, Tausch C, Stierer M, on behalf of the ABCSG (2005) Extended adjuvant treatment with anastrozole: results from the Austrian Breast and Colorectal Cancer Study Group Trial 6a (ABCSG-6a). J Clin Oncol 23(16):10S (#526, abstract)
26. Janicke F (2004) Are all aromatase inhibitors the same? A review of the current evidence. Breast 13(Suppl 1):S10-S18
27. Karnon J, Delea T, Johnston SR, Smith R, Brandman J, Sung J, Goss PE (2006) Cost effectiveness of extended adjuvant letrozole in postmenopausal women after adjuvant tamoxifen therapy: the UK perspective. Pharmacoeconomics 24:237-250
28. Kaufmann M, Rody A (2005) Long-term risk of breast cancer recurrence: the need for extended adjuvant therapy. J Cancer Res Clin Oncol 131:487-494
29. Kennecke HF, Olivotto IA, Speers C, Norris B, Chia SK, Bryce C, Gelmon KA (2007) Late risk of relapse and mortality among postmenopausal women with estrogen responsive early breast cancer after 5 years of tamoxifen. Ann Oncol 18:45-51
30. Lamerato L, Havstad S, Gandhi S, Jones D, Chlebowski R (2005) Breast cancer recurrence and related mortality in US pts with early breast cancer. J Clin Oncol 25(16S):62s (#738, abstract)
31. Lester J, Dodwell D, McCloskey E, Coleman R (2005) The causes and treatment of bone loss associated with carcinoma of the breast. Cancer Treat Rev 31:115-142
32. Mackey JR, Joy AA (2005) Skeletal health in postmenopausal survivors of early breast cancer. Int J Cancer 114:1010-1015
33. Mamounas EP (2001) Adjuvant exemestane therapy after 5 years of tamoxifen: rationale for the NSABP B-33 trial. Oncology (Huntingt) 15:35-39
34. Mamounas E, Jeong J-H, Wickerham L, Smith R, Geyer C, Ganz P, Land S, Hutchins L, Eisen A, Ingle J, Costantino J, Wolmark N (2006) Benefit from exemestane (EXE) as extended adjuvant therapy after 5 years of tamoxifen (TAM): intent-to-treat analysis of NSABP B-33. Breast Cancer Res Treat 100(Suppl 1):S22 (#49, abstract)
35. Muss HB, Tu D, Ingle JN, Martino S, Robert NJ, Pater JL, Whelan T, Palmer MJ, Piccart MJ, Shepherd LE, Pritchard KI, He Z, Goss PE (2006) The benefits of letrozole in postmenopausal women with early stage breast cancer who have had five years of tamoxifen are independent of age. Breast Cancer Res Treat 100(Suppl 1):S23 (#102, abstract)
36. National Comprehensive Cancer Network (2003) Clinical practice guidelines in oncology: breast cancer, Version 3. Available at: http://www.ingentaconnect. com/content/jandb/jnccn/2003/00000001/00000002/art00004. Accessed 14 January, 2004
37. Ouagari KE, Karnon J, Delea T, Talbot W, Brandman J (2007) Cost-effectiveness of letrozole in the extended adjuvant treatment of women with early breast cancer. Breast Cancer Res Treat 101:37-49
38. Pater J, Tu D, Shepherd L, Ingle JN, Goss PE (2007) Decision making in adjuvant trials in breast cancer: the NCIC CTG MA.17 trial as an example. Breast Cancer Res Treat, May 3 [Epub ahead of print]
39. Perez EA, Josse RG, Pritchard KI, Ingle JN, Martino S, Findlay BP, Shenkier TN, Tozer RG, Palmer MJ, Shepherd LE, Liu S, Tu D, Goss PE (2006) Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17. J Clin Oncol 24:3629-3635
40. Robert NJ, Goss PE, Ingle JN, Tu D, Shepherd LE, Palmer MJ, Pater JM (2006) Updated analysis of NCIC CTG MA.17 (letrozole vs. placebo to letrozole vs. placebo) post unblinding. J Clin Oncol 24(18S):15s (#550, abstract)
41. Schmid M, Jakesz R, Samonigg H, Kubista E, Gnant M, Menzel C, Seifert M, Haider K, Taucher S, Mlineritsch B, Steindorfer P, Kwasny W, Stierer M, Tausch C, Fridrik M, Wette V, Steger G, Hausmaninger H (2003) Randomized trial of tamoxifen versus tamoxifen plus aminoglutethimide as adjuvant treatment in postmenopausal breast cancer patients with hormone receptor-positive disease: Austrian Breast and Colorectal Cancer Study Group Trial 6. J Clin Oncol 21:984-990
42. Smith IE (2004) Aromatase inhibitors-extending the benefits of adjuvant therapy beyond tamoxifen. Breast 13(Suppl 1):S3-S9
43. Vachon CM, Ingle JN, Suman VJ, Scott CG, Gottardt H, Olson JE, Goss PE (2007) Pilot study of the impact of letrozole vs. placebo on breast density in women completing 5 years of tamoxifen. Breast 16:204-210
44. Wasan KM, Goss PE, Pritchard PH, Shepherd L, Palmer MJ, Liu S, Tu D, Ingle JN, Heath M, Deangelis D, Perez EA (2005) The influence of letrozole on serum lipid concentrations in postmenopausal women with primary breast cancer who have completed 5 years of adjuvant tamoxifen (NCIC CTG MA.17L). Ann Oncol 16:707-715
45. Whelan TJ, Goss PE, Ingle JN, Pater JL, Tu D, Pritchard K, Liu S, Shepherd LE, Palmer M, Robert NJ, Martino S, Muss HB (2005) Assessment of quality of life in MA.17: a randomized, placebo-controlled trial of letrozole after 5 years of tamoxifen in postmenopausal women. J Clin Oncol 23:6931-6940